The ability to adjust conformations in response to the polarity of the environment, ie
molecular chameleonicity, is considered to be important for conferring both high aqueous …

Introduction With the introduction of highly effective and safe therapies with next-generation
direct-acting antivirals (DAAs), that act without interferon, hepatitis C virus (HCV) infection …

Background: The clinical outcomes of antiretroviral drugs may be modified through drug
interactions; thus, it is important to update the drug interactions in people living with HIV …

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Although
interferon-free direct-acting antivirals have led to significant advancements in the treatment …

The inhibition of P-glycoprotein (ABCB1) could lead to increased drug plasma
concentrations and hence increase drug toxicity. The evaluation of a drug's ability to inhibit …

BACKGROUND: Direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) have
varying potentials for drug-drug interactions (DDIs). OBJECTIVES: To (1) identify prevalence …

Introduction: Sofosbuvir/velpatasvir is a combination of direct-acting antivirals with
pangenotypic activity for treatment of chronic hepatitis C virus infection. It was approved in …

Introduction Due to concerns over potential interactions between some hepatitis C direct-
acting antivirals (DAAs) and opioids, we describe adverse event (AE) reports of concomitant …

This case report describes a pharmacokinetic drug–drug interaction between crizotinib, a
tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct‐acting antiviral drug, leading to …

Abstract Objective: Patients with chronic Hepatitis C Virus Infection (HCV) present high rates
of comorbidity and polypharmacy. We aimed to assess the additional actions and resource …